News & Events

Düsseldorf, 15 October 2018.

Prostate cancer is the second leading cause of cancer death for men in many parts of the world. For imaging, PSMA-based radio tracers target the PSMA  (Prostate Specific Membrane Antigen) transmembrane glycoprotein, which is strongly upregulated in prostate cancer cells. In this way, the PET tracer provides important molecular information on cancer and metastases localization within the prostate.

AllinOne family versatility proven

Three months after its approval by the American FDA, Trasis’ FDG Dual method obtains its Market Authorization for Belgium and the Netherlands.

Trasis and Radboud Translational Medicine (RTM) worked together and finalized the Marketing Authorization National Phase for FDG production on AllinOne synthesizers.

Ans, 11 October 2018 – We are pleased to announce that we have entered into an agreement with RQS. Ruffani Quality Solutions will be our agent and provide service support for Germany and Austria.

With decades of experience and jointly to Trasis, RQS are committed to listening to our customers in order to provide the most effective solution. Located in Heideneau, RQS is also a valued partner and able to offer technical support in Germany and Austria.

Join us and discover the AllinOne, the most versatile module for synthesis of 18F, 68Ga, 11C, 177Lu, 64 Cu, ...

http://www.trasis.com/products/allinone-universal-synthesizer

Trasis and Shertech Laboratories, received FDA approval of the [18F]FDG Dual process on AllinOne synthesizers.

Trasis and Shertech Laboratories “hand to hand” work was recently rewarded with approval of a supplemental abbreviated New Drug Application and thus receiving a Marketing Authorization from the U.S. Food and Drug Administration for the [18F]FDG Dual process on AllinOne modules.